TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases (Q38165027)

30 August 2017

TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases (English)

1 reference

30 August 2017

chronic liver disease

0 references

1 reference

Koichi Matsuzaki

1

1 reference

PubMed ID

24263677

30 August 2017

Toshihito Seki

series ordinal

2

1 reference

PubMed ID

24263677

30 August 2017

Kazuichi Okazaki

series ordinal

3

1 reference

30 August 2017

22 November 2013

1 reference

Journal of Gastroenterology

30 August 2017

1 reference

30 August 2017

49

1 reference

30 August 2017

6

1 reference

30 August 2017

971-981

1 reference

Epidemiology of viral hepatitis and hepatocellular carcinoma

30 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Evolving challenges in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Regulation of differentiation by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGFβ signalling in context

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGF-β signaling in onset and progression of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGF-beta signalling from cell membrane to nucleus through SMAD proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Cyclin-dependent kinases regulate the antiproliferative function of Smads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Transforming growth factor-{beta}-inducible phosphorylation of Smad3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Reversible Smad-dependent signaling between tumor suppression and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

c-Jun N-terminal kinase 1 promotes transforming growth factor-β1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

An integrated expression profiling reveals target genes of TGF-β and TNF-α possibly mediated by microRNAs in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-beta-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

A negative feedback control of transforming growth factor-beta signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Axin and GSK3- control Smad3 protein stability and modulate TGF- signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Smad phospho-isoforms direct context-dependent TGF-β signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Smad3 phosphorylation by cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Phospho-control of TGF-beta superfamily signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Smad phosphoisoform signaling specificity: the right place at the right time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Non-Smad pathways in TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Non-Smad TGF-beta signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Metastasis is driven by sequential elevation of H-ras and Smad2 levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Differential expression of transforming growth factor-beta and its receptors in hepatocytes and nonparenchymal cells of rat liver after CCl4 administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Modulation of transforming growth factor beta function in hepatocytes and hepatic stellate cells in rat liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Butein inhibits ethanol-induced activation of liver stellate cells through TGF-β, NFκB, p38, and JNK signaling pathways and inhibition of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Update on the pathophysiology of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Defects in TGF-beta signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

How to modulate inflammatory cytokines in liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Distortion of autocrine transforming growth factor β signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

HBx gene of hepatitis B virus induces liver cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Altered innate immunity in chronic hepatitis C infection: cause or effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Genetics of hepatocellular tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0910-2

Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb

21 January 2018

1 reference

12 December 2020

SKI knockdown inhibits human melanoma tumor growth in vivo

1 reference

12 December 2020

Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma

1 reference

12 December 2020

Molecular pathogenesis of human hepatocellular carcinoma

1 reference

12 December 2020

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

1 reference

12 December 2020

Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

1 reference

12 December 2020

Modulation of the transforming growth factor-beta1-induced Smad phosphorylation by the extracellular matrix receptor beta1-integrin

1 reference

12 December 2020

1 reference

12 December 2020

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Gr

1 reference

12 December 2020

Autocrine transforming growth factor beta suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells

1 reference

12 December 2020

Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial

1 reference

12 December 2020

p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts

1 reference

12 December 2020

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

12 December 2020

Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth

1 reference

12 December 2020

10.1007/S00535-013-0910-2

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24263677